A detailed history of Nuveen Asset Management, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 441,092 shares of ALNY stock, worth $104 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
441,092
Previous 588,469 25.04%
Holding current value
$104 Million
Previous $143 Million 15.15%
% of portfolio
0.04%
Previous 0.04%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$233.81 - $287.01 $34.5 Million - $42.3 Million
-147,377 Reduced 25.04%
441,092 $121 Million
Q2 2024

Aug 09, 2024

BUY
$143.31 - $247.0 $11 Million - $18.9 Million
76,491 Added 14.94%
588,469 $143 Million
Q1 2024

May 13, 2024

SELL
$146.51 - $198.2 $4.61 Million - $6.23 Million
-31,433 Reduced 5.78%
511,978 $76.5 Million
Q4 2023

Feb 14, 2024

SELL
$151.41 - $196.57 $461,346 - $598,948
-3,047 Reduced 0.56%
543,411 $104 Million
Q3 2023

Nov 14, 2023

SELL
$170.77 - $211.65 $1.06 Million - $1.32 Million
-6,221 Reduced 1.13%
546,458 $96.8 Million
Q2 2023

Aug 14, 2023

SELL
$185.01 - $212.05 $10.4 Million - $12 Million
-56,427 Reduced 9.26%
552,679 $105 Million
Q1 2023

May 15, 2023

SELL
$182.66 - $235.53 $1.74 Million - $2.25 Million
-9,538 Reduced 1.54%
609,106 $122 Million
Q4 2022

Feb 14, 2023

SELL
$185.53 - $241.31 $2.96 Billion - $3.85 Billion
-15,974,624 Reduced 96.27%
618,644 $147 Million
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $2.26 Billion - $3.78 Billion
16,296,223 Added 5486.11%
16,593,268 $3.32 Billion
Q2 2022

Aug 15, 2022

SELL
$120.42 - $169.29 $7.83 Million - $11 Million
-64,990 Reduced 17.95%
297,045 $43.3 Million
Q1 2022

May 16, 2022

SELL
$127.18 - $173.91 $29.1 Million - $39.7 Million
-228,509 Reduced 38.69%
362,035 $58.8 Million
Q4 2021

Feb 14, 2022

SELL
$159.56 - $209.29 $28.2 Million - $36.9 Million
-176,488 Reduced 23.01%
590,544 $100 Million
Q3 2021

Nov 12, 2021

BUY
$169.75 - $207.73 $19.4 Million - $23.7 Million
114,024 Added 17.46%
767,032 $145 Million
Q2 2021

Aug 16, 2021

BUY
$128.63 - $176.89 $7.33 Million - $10.1 Million
57,008 Added 9.57%
653,008 $111 Million
Q1 2021

May 17, 2021

SELL
$126.83 - $175.69 $342,441 - $474,363
-2,700 Reduced 0.45%
596,000 $84.1 Million
Q4 2020

May 17, 2021

SELL
$122.97 - $147.0 $507,128 - $606,228
-4,124 Reduced 0.68%
598,700 $77.8 Million
Q4 2020

Feb 16, 2021

BUY
$122.97 - $147.0 $21.6 Million - $25.8 Million
175,453 Added 41.05%
602,824 $78.3 Million
Q3 2020

Nov 16, 2020

SELL
$121.19 - $165.49 $3.17 Million - $4.34 Million
-26,197 Reduced 5.78%
427,371 $62.2 Million
Q2 2020

Aug 14, 2020

SELL
$104.21 - $156.44 $6.39 Million - $9.59 Million
-61,300 Reduced 11.91%
453,568 $67.2 Million
Q1 2020

May 14, 2020

BUY
$93.12 - $133.99 $10.4 Million - $14.9 Million
111,311 Added 27.58%
514,868 $56 Million
Q4 2019

Feb 14, 2020

SELL
$74.51 - $124.23 $943,073 - $1.57 Million
-12,657 Reduced 3.04%
403,557 $46.5 Million
Q3 2019

Nov 14, 2019

BUY
$70.9 - $87.82 $1.81 Million - $2.24 Million
25,552 Added 6.54%
416,214 $33.5 Million
Q2 2019

Aug 15, 2019

BUY
$65.86 - $92.79 $25.7 Million - $36.2 Million
390,662 New
390,662 $28.3 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.